ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001


SEARCH JOBS
Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.


 Key Statistics


Email: contact@seagen.com
Ownership: Public

Web Site: Seattle Genetics, Inc.
Employees:
Symbol: SGEN
 



Industry
Biotechnology


Collaborations

Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 

MedImmune 





 Company News
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014 10:45:08 AM
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY) ADCETRIS Phase 3 Demonstrated Statistically Significant Improvement In Progression-Free Survival 12/9/2014 8:06:20 AM
Seattle Genetics, Inc. (SGEN) Presents Data From SGN-CD19A Antibody-Drug Conjugate At American Society of Hematology Annual Meeting 12/8/2014 2:19:19 PM
Seattle Genetics, Inc. (SGEN) And Takeda (TKPYY) Announce Four-Year Survival Data From ADCETRIS® (Brentuximab Vedotin) Pivotal Trial In Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma At American Society of Hematology Annual Meeting 12/8/2014 11:29:51 AM
Seattle Genetics, Inc. (SGEN) Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations In Frontline And Salvage Hodgkin Lymphoma At American Society of Hematology Annual Meeting 12/8/2014 11:06:19 AM
Seattle Genetics, Inc. (SGEN) And Takeda (TKPYY) Report Phase 3 AETHERA Clinical Trial Data From ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At Risk Of Relapse At American Society of Hematology Annual Meeting 12/8/2014 9:56:13 AM
Seattle Genetics, Inc. (SGEN) Names New General Counsel And Executive Vice President, Legal Affairs 11/18/2014 9:24:50 AM
Seattle Genetics, Inc. (SGEN) To Present Clinical Data From Broad ADCETRIS® (Brentuximab Vedotin) Development Program And Novel Antibody-Drug Conjugates At American Society of Hematology 2014 11/7/2014 9:40:01 AM
Seattle Genetics, Inc. (SGEN) To Present At Credit Suisse Healthcare Conference 11/4/2014 10:06:43 AM
Seattle Genetics, Inc. (SGEN) Reports Third Quarter 2014 Financial Results 10/31/2014 9:11:12 AM
12345678910...